



OFFICIAL KICK OFF MEETING
MARCH 28th 2012, Shanghai, CHINA
FP7 INCOLAB

**Toward enhancing activities of European institutions
in the FDUSCC – IM cancer research joint institute in China**

International Cooperation Program



Sistema Sanitario Regione Lombardia

Transgene signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Fudan University Shanghai Cancer Center and European Academic Laboratories

An important international scientific cooperation program coordinated by Transgene, called Immunocan (www.immunocan.org), has recently received approval from the European Commission as a FP7 (Seventh Framework Program) funded research program. Immunocan aims at increasing the transnational medical research cooperation between European countries and China, and more particularly at conducting research to identify immunological characteristics in Chinese cancer patients as medical biomarkers for the personalized prognosis of patients. The Fudan University Shanghai Cancer Centre (China), the University of Copenhagen (Denmark), the IRCCS (Istituto Nazionale dei Tumori) Foundation (Italy) and the Medizinische Hochschule from Hannover (Germany) are associated in this collaborative program. Immunocan will be conducted in the laboratories of the joint institute for cancer research of the Fudan University Shanghai Cancer Centre and Institut Mérieux (“FDUSCC-IM”) in Shanghai, in which Transgene is also a partner. Under this FP7-sponsored program, the goal of the partners and of the European Commission is to build a Euro-Asian reference centre for medical and scientific research on cancer. This program is running from January 1st 2012 for 4 years and benefit from 2 million € (16.6 million CNY) funding from the European Commission.